{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:54:16Z","timestamp":1794956056901,"version":"4.9.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00520-025-09286-z","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T03:50:26Z","timestamp":1740973826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline"],"prefix":"10.1007","volume":"33","author":[{"given":"Mellar P.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila S.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Paice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Roeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Bohlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"9286_CR1","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","volume":"377","author":"RK Portenoy","year":"2011","unstructured":"Portenoy RK (2011) Treatment of cancer pain. Lancet 377:2236\u20132247","journal-title":"Lancet"},{"key":"9286_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2015.12.011","volume":"99","author":"S Mercadante","year":"2016","unstructured":"Mercadante S, Bruera E (2016) Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol 99:241\u2013248","journal-title":"Crit Rev Oncol Hematol"},{"key":"9286_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.2147\/JPR.S170269","volume":"11","author":"E Treillet","year":"2018","unstructured":"Treillet E, Laurent S, Hadjiat Y (2018) Practical management of opioid rotation and equianalgesia. J Pain Res 11:2587\u20132601","journal-title":"J Pain Res"},{"key":"9286_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1526-4637.2012.01357.x","volume":"13","author":"LR Webster","year":"2012","unstructured":"Webster LR, Fine PG (2012) Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 13:562\u2013570","journal-title":"Pain Med"},{"key":"9286_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1533-2500.2009.00335.x","volume":"10","author":"KC Vissers","year":"2010","unstructured":"Vissers KC, Besse K, Hans G et al (2010) Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 10:85\u201393","journal-title":"Pain Pract"},{"key":"9286_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5055\/jom.2008.0027","volume":"4","author":"A Vadalouca","year":"2008","unstructured":"Vadalouca A, Moka E, Argyra E et al (2008) Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag 4:213\u2013250","journal-title":"J Opioid Manag"},{"key":"9286_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/026921639801200111","volume":"12","author":"R Twycross","year":"1998","unstructured":"Twycross R (1998) Opioid rotation: does it have a role? Palliat Med 12:60\u201363","journal-title":"Palliat Med"},{"key":"9286_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1185\/03007990903120158","volume":"25","author":"NE Slatkin","year":"2009","unstructured":"Slatkin NE (2009) Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 25:2133\u20132150","journal-title":"Curr Med Res Opin"},{"key":"9286_CR9","first-page":"135","volume":"115","author":"M Schuster","year":"2018","unstructured":"Schuster M, Bayer O, Heid F et al (2018) Opioid rotation in cancer pain treatment. Dtsch Arztebl Int 115:135\u2013142","journal-title":"Dtsch Arztebl Int"},{"key":"9286_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1089\/jpm.2022.0266","volume":"25","author":"A Reddy","year":"2022","unstructured":"Reddy A, Sinclair C, Crawford GB et al (2022) Opioid rotation and conversion ratios used by palliative care professionals: an international survey. J Palliat Med 25:1557\u20131562","journal-title":"J Palliat Med"},{"key":"9286_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12325-012-0051-7","volume":"29","author":"SR Nalamachu","year":"2012","unstructured":"Nalamachu SR (2012) Opioid rotation in clinical practice. Adv Ther 29:849\u2013863","journal-title":"Adv Ther"},{"key":"9286_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G","volume":"86","author":"S Mercadante","year":"1999","unstructured":"Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856\u20131866","journal-title":"Cancer"},{"key":"9286_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jpainsymman.2009.06.001","volume":"38","author":"H Knotkova","year":"2009","unstructured":"Knotkova H, Fine PG, Portenoy RK (2009) Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 38:426\u2013439","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0165-6147(00)01616-3","volume":"22","author":"GW Pasternak","year":"2001","unstructured":"Pasternak GW (2001) Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22:67\u201370","journal-title":"Trends Pharmacol Sci"},{"key":"9286_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/164_2019_270","volume":"258","author":"GW Pasternak","year":"2020","unstructured":"Pasternak GW, Childers SR, Pan YX (2020) Emerging insights into mu opioid pharmacology. Handb Exp Pharmacol 258:89\u2013125","journal-title":"Handb Exp Pharmacol"},{"key":"9286_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.apha.2017.09.006","volume":"82","author":"GW Pasternak","year":"2018","unstructured":"Pasternak GW (2018) Mu opioid pharmacology: 40 years to the promised land. Adv Pharmacol 82:261\u2013291","journal-title":"Adv Pharmacol"},{"key":"9286_CR17","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0024-3205(01)01008-6","volume":"68","author":"GW Pasternak","year":"2001","unstructured":"Pasternak GW (2001) Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. Life Sci 68:2213\u20132219","journal-title":"Life Sci"},{"key":"9286_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jpainsymman.2009.06.002","volume":"38","author":"PG Fine","year":"2009","unstructured":"Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence R et al (2009) Establishing \u201cbest practices\u201d for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 38:418\u201325","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1526-4637.2012.01356.x","volume":"13","author":"LR Webster","year":"2012","unstructured":"Webster LR, Fine PG (2012) Overdose deaths demand a new paradigm for opioid rotation. Pain Med 13:571\u2013574","journal-title":"Pain Med"},{"key":"9286_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","volume":"41","author":"JA Paice","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D et al (2023) Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 41:914\u2013930","journal-title":"J Clin Oncol"},{"key":"9286_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00520-024-08710-0","volume":"32","author":"MP Davis","year":"2024","unstructured":"Davis MP, Davies A, McPherson ML et al (2024) Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline. Support Care Cancer 32:542","journal-title":"Support Care Cancer"},{"key":"9286_CR22","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","volume":"30","author":"DA Loblaw","year":"2012","unstructured":"Loblaw DA, Prestrud AA, Somerfield MR et al (2012) American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 30:3136\u20133140","journal-title":"J Clin Oncol"},{"key":"9286_CR23","first-page":"99","volume":"42","author":"M Falzarano","year":"2013","unstructured":"Falzarano M, Pinto Zipp G (2013) Seeking consensus through the use of the Delphi technique in health sciences research. J Allied Health 42:99\u2013105","journal-title":"J Allied Health"},{"key":"9286_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/01.NND.0000434028.30432.34","volume":"30","author":"M Asselin","year":"2014","unstructured":"Asselin M, Harper M (2014) Revisiting the Delphi technique: implications for nursing professional development. J Nurses Prof Dev 30:11\u201315","journal-title":"J Nurses Prof Dev"},{"key":"9286_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2648.2006.03716.x","volume":"53","author":"S Keeney","year":"2006","unstructured":"Keeney S, Hasson F, McKenna H (2006) Consulting the oracle: ten lessons from using the Delphi technique in nursing research. J Adv Nurs 53:205\u2013212","journal-title":"J Adv Nurs"},{"key":"9286_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0304-3959(92)90163-6","volume":"50","author":"BS Galer","year":"1992","unstructured":"Galer BS, Rowbotham MC, Miller KV et al (1992) Treatment of inflammatory, neuropathic and sympathetically maintained pain in a patient with Sjogren\u2019s syndrome. Pain 50:205\u2013208","journal-title":"Pain"},{"key":"9286_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(92)90192-E","volume":"49","author":"BS Galer","year":"1992","unstructured":"Galer BS, Coyle N, Pasternak GW et al (1992) Individual variability in the response to different opioids: report of five cases. Pain 49:87\u201391","journal-title":"Pain"},{"key":"9286_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1399-6576.1997.tb04630.x","volume":"41","author":"GW Hanks","year":"1997","unstructured":"Hanks GW, Forbes K (1997) Opioid responsiveness. Acta Anaesthesiol Scand 41:154\u2013158","journal-title":"Acta Anaesthesiol Scand"},{"key":"9286_CR29","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/oxfordjournals.bmb.a072503","volume":"47","author":"GW Hanks","year":"1991","unstructured":"Hanks GW (1991) Opioid-responsive and opioid-non-responsive pain in cancer. Br Med Bull 47:718\u2013731","journal-title":"Br Med Bull"},{"key":"9286_CR30","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/pm\/pnx178","volume":"19","author":"D Koyyalagunta","year":"2018","unstructured":"Koyyalagunta D, Bruera E, Engle MP et al (2018) Compliance with opioid therapy: distinguishing clinical characteristics and demographics among patients with cancer pain. Pain Med 19:1469\u20131477","journal-title":"Pain Med"},{"key":"9286_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","volume":"87","author":"GF Koob","year":"2020","unstructured":"Koob GF (2020) Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry 87:44\u201353","journal-title":"Biol Psychiatry"},{"key":"9286_CR32","doi-asserted-by":"publisher","first-page":"e1368232023","DOI":"10.1523\/JNEUROSCI.1368-23.2023","volume":"44","author":"X Han","year":"2024","unstructured":"Han X, Pinto LG, Vilar B et al (2024) Opioid-induced hyperalgesia and tolerance are driven by HCN ion channels. J Neurosci 44:e1368232023","journal-title":"J Neurosci"},{"key":"9286_CR33","doi-asserted-by":"publisher","first-page":"1297931","DOI":"10.3389\/fphar.2023.1297931","volume":"14","author":"M Echeverria-Villalobos","year":"2023","unstructured":"Echeverria-Villalobos M, Tortorici V, Brito BE et al (2023) The role of neuroinflammation in the transition of acute to chronic pain and the opioid-induced hyperalgesia and tolerance. Front Pharmacol 14:1297931","journal-title":"Front Pharmacol"},{"key":"9286_CR34","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.ynpai.2023.100146","volume":"14","author":"D Reddy","year":"2023","unstructured":"Reddy D, Wickman JR, Ajit SK (2023) Epigenetic regulation in opioid induced hyperalgesia. Neurobiol Pain 14:100146","journal-title":"Neurobiol Pain"},{"key":"9286_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5055\/jom.2006.0041","volume":"2","author":"MJ Baron","year":"2006","unstructured":"Baron MJ, McDonald PW (2006) Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2:277\u2013282","journal-title":"J Opioid Manag"},{"key":"9286_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.36076\/ppj.2009\/12\/679","volume":"12","author":"SM Silverman","year":"2009","unstructured":"Silverman SM (2009) Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 12:679\u2013684","journal-title":"Pain Physician"},{"key":"9286_CR37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jpain.2020.01.005","volume":"21","author":"MC Rowbotham","year":"2020","unstructured":"Rowbotham MC, Wallace M (2020) Evolution of analgesic tolerance and opioid-induced hyperalgesia over 6 months: double-blind randomized trial incorporating experimental pain models. J Pain 21:1031\u20131046","journal-title":"J Pain"},{"key":"9286_CR38","doi-asserted-by":"crossref","unstructured":"Zylicz Z, Twycross R (2008) Opioid-induced hyperalgesia may be more frequent than previously thought. J Clin Oncol 26:1564; author reply 1565","DOI":"10.1200\/JCO.2007.15.6919"},{"key":"9286_CR39","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s11606-018-4490-y","volume":"33","author":"MC Haverfield","year":"2018","unstructured":"Haverfield MC, Giannitrapani K, Timko C et al (2018) Patient-centered pain management communication from the patient perspective. J Gen Intern Med 33:1374\u20131380","journal-title":"J Gen Intern Med"},{"key":"9286_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/1049909120945599","volume":"38","author":"S Firdous","year":"2021","unstructured":"Firdous S, Berger A, Jehangir W et al (2021) How should we assess pain: do patients prefer a quantitative or qualitative scale? A study of patient preferences. Am J Hosp Palliat Care 38:383\u2013390","journal-title":"Am J Hosp Palliat Care"},{"key":"9286_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/0269216313486310","volume":"28","author":"J Gibbins","year":"2014","unstructured":"Gibbins J, Bhatia R, Forbes K et al (2014) What do patients with advanced incurable cancer want from the management of their pain? A qualitative study. Palliat Med 28:71\u201378","journal-title":"Palliat Med"},{"key":"9286_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpainsymman.2008.01.010","volume":"37","author":"S Jeon","year":"2009","unstructured":"Jeon S, Given CW, Sikorskii A et al (2009) Do interference-based cut-points differentiate mild, moderate, and severe levels of 16 cancer-related symptoms over time? J Pain Symptom Manage 37:220\u2013232","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pain.2004.09.014","volume":"113","author":"SM Paul","year":"2005","unstructured":"Paul SM, Zelman DC, Smith M et al (2005) Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 113:37\u201344","journal-title":"Pain"},{"key":"9286_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0304-3959(03)00274-4","volume":"106","author":"DC Zelman","year":"2003","unstructured":"Zelman DC, Hoffman DL, Seifeldin R et al (2003) Development of a metric for a day of manageable pain control: derivation of pain severity cut-points for low back pain and osteoarthritis. Pain 106:35\u201342","journal-title":"Pain"},{"key":"9286_CR45","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jpainsymman.2004.02.022","volume":"28","author":"DC Zelman","year":"2004","unstructured":"Zelman DC, Smith MY, Hoffman D et al (2004) Acceptable, manageable, and tolerable days: patient daily goals for medication management of persistent pain. J Pain Symptom Manage 28:474\u2013487","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR46","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1089\/jpm.2018.0490","volume":"22","author":"S Okayama","year":"2019","unstructured":"Okayama S, Matsuda Y, Yoshikawa Y (2019) A comparative study of opioid switching to methadone for cancer pain control in successful and unsuccessful cases. J Palliat Med 22:844\u2013847","journal-title":"J Palliat Med"},{"key":"9286_CR47","doi-asserted-by":"publisher","first-page":"109932","DOI":"10.1016\/j.drugalcdep.2023.109932","volume":"248","author":"V Mocanu","year":"2023","unstructured":"Mocanu V, Bozinoff N, Wood E et al (2023) Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: secondary analysis of a pragmatic randomized trial. Drug Alcohol Depend 248:109932","journal-title":"Drug Alcohol Depend"},{"key":"9286_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12904-023-01160-1","volume":"22","author":"N Michael","year":"2023","unstructured":"Michael N, Sulistio M, Wojnar R et al (2023) Methadone rotation versus other opioid rotation for refractory cancer induced bone pain: protocol of an exploratory randomised controlled open-label study. BMC Palliat Care 22:42","journal-title":"BMC Palliat Care"},{"issue":"Pt B","key":"9286_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuropharm.2013.03.039","volume":"76","author":"GW Pasternak","year":"2014","unstructured":"Pasternak GW (2014) Opioids and their receptors: are we there yet? Neuropharmacology 76(Pt B):198\u2013203","journal-title":"Neuropharmacology"},{"key":"9286_CR50","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.2013.53.1079","volume":"32","author":"GW Pasternak","year":"2014","unstructured":"Pasternak GW (2014) Opiate pharmacology and relief of pain. J Clin Oncol 32:1655\u20131661","journal-title":"J Clin Oncol"},{"key":"9286_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.aat.2010.12.008","volume":"49","author":"G Pasternak","year":"2011","unstructured":"Pasternak G, Pan YX (2011) Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan 49:21\u201325","journal-title":"Acta Anaesthesiol Taiwan"},{"issue":"Suppl 1","key":"9286_CR52","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.neuropharm.2004.07.004","volume":"47","author":"GW Pasternak","year":"2004","unstructured":"Pasternak GW (2004) Multiple opiate receptors: deja vu all over again. Neuropharmacology 47(Suppl 1):312\u2013323","journal-title":"Neuropharmacology"},{"key":"9286_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejpain.2004.12.003","volume":"9","author":"HC Muller-Busch","year":"2005","unstructured":"Muller-Busch HC, Lindena G, Tietze K et al (2005) Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain 9:571\u2013579","journal-title":"Eur J Pain"},{"key":"9286_CR54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/0885-3924(95)90924-C","volume":"10","author":"ND de Stoutz","year":"1995","unstructured":"de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378\u2013384","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR55","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s005200000153","volume":"8","author":"M Kloke","year":"2000","unstructured":"Kloke M, Rapp M, Bosse B et al (2000) Toxicity and\/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 8:479\u201386","journal-title":"Support Care Cancer"},{"key":"9286_CR56","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00002508-200309000-00002","volume":"19","author":"AR Gammaitoni","year":"2003","unstructured":"Gammaitoni AR, Fine P, Alvarez N et al (2003) Clinical application of opioid equianalgesic data. Clin J Pain 19:286\u2013297","journal-title":"Clin J Pain"},{"key":"9286_CR57","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ctrv.2006.03.001","volume":"32","author":"S Mercadante","year":"2006","unstructured":"Mercadante S, Bruera E (2006) Opioid switching: a systematic and critical review. Cancer Treat Rev 32:304\u2013315","journal-title":"Cancer Treat Rev"},{"key":"9286_CR58","first-page":"589","volume":"7","author":"HS Smith","year":"2014","unstructured":"Smith HS, Peppin JF (2014) Toward a systematic approach to opioid rotation. J Pain Res 7:589\u2013608","journal-title":"J Pain Res"},{"issue":"Suppl 2","key":"9286_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/1158413-S0-000000000-00000","volume":"30","author":"A Gatti","year":"2010","unstructured":"Gatti A, Reale C, Luzi M et al (2010) Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clin Drug Investig 30(Suppl 2):39\u201347","journal-title":"Clin Drug Investig"},{"key":"9286_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJMp1504023","volume":"373","author":"TJ Kaptchuk","year":"2015","unstructured":"Kaptchuk TJ, Miller FG (2015) Placebo effects in medicine. N Engl J Med 373:8\u20139","journal-title":"N Engl J Med"},{"key":"9286_CR61","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0140-6736(78)92762-9","volume":"2","author":"JD Levine","year":"1978","unstructured":"Levine JD, Gordon NC, Fields HL (1978) The mechanism of placebo analgesia. Lancet 2:654\u2013657","journal-title":"Lancet"},{"key":"9286_CR62","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3959(00)00486-3","volume":"90","author":"M Amanzio","year":"2001","unstructured":"Amanzio M, Pollo A, Maggi G et al (2001) Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 90:205\u2013215","journal-title":"Pain"},{"key":"9286_CR63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000490354","volume":"87","author":"AWM Evers","year":"2018","unstructured":"Evers AWM, Colloca L, Blease C et al (2018) Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother Psychosom 87:204\u2013210","journal-title":"Psychother Psychosom"},{"key":"9286_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/cncr.29688","volume":"122","author":"A Reddy","year":"2016","unstructured":"Reddy A, Tayjasanant S, Haider A et al (2016) The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients. Cancer 122:149\u2013156","journal-title":"Cancer"},{"key":"9286_CR65","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1634\/theoncologist.2014-0130","volume":"19","author":"A Reddy","year":"2014","unstructured":"Reddy A, Yennurajalingam S, Desai H et al (2014) The opioid rotation ratio of hydrocodone to strong opioids in cancer patients. Oncologist 19:1186\u20131193","journal-title":"Oncologist"},{"key":"9286_CR66","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/pds.3945","volume":"25","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Degenhardt L, Hoban B et al (2016) A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf 25:733\u2013737","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9286_CR67","first-page":"153","volume":"9","author":"J Fudin","year":"2016","unstructured":"Fudin J, Pratt Cleary J, Schatman ME (2016) The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development. J Pain Res 9:153\u2013156","journal-title":"J Pain Res"},{"key":"9286_CR68","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5055\/jom.2022.0751","volume":"18","author":"HC Dinges","year":"2022","unstructured":"Dinges HC, Schubert AK, Rucker G et al (2022) Equianalgesic potency ratios of opioids used in patient-controlled analgesia: a network meta-analysis. J Opioid Manag 18:567\u2013586","journal-title":"J Opioid Manag"},{"key":"9286_CR69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1526-4637.2008.00461.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9:595\u2013612","journal-title":"Pain Med"},{"key":"9286_CR70","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","volume":"16","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, Groff L, Brunelli C et al (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216\u20133221","journal-title":"J Clin Oncol"},{"key":"9286_CR71","unstructured":"Estfan B, LeGrand SB, Walsh D et al (2005) Opioid rotation in cancer patients: pros and cons. Oncology (Williston Park) 19:511\u20136; discussion 516\u20138, 521\u20133, 527\u20138"},{"key":"9286_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1191\/0269216303pm824oa","volume":"17","author":"M Takahashi","year":"2003","unstructured":"Takahashi M, Ohara T, Yamanaka H et al (2003) The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment. Palliat Med 17:673\u2013678","journal-title":"Palliat Med"},{"key":"9286_CR73","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0304-3959(86)90234-4","volume":"25","author":"GK Gourlay","year":"1986","unstructured":"Gourlay GK, Cherry DA, Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297\u2013312","journal-title":"Pain"},{"key":"9286_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1365-2354.1999.00133.x","volume":"8","author":"CF Scholes","year":"1999","unstructured":"Scholes CF, Gonty N, Trotman IF (1999) Methadone titration in opioid-resistant cancer pain. Eur J Cancer Care (Engl) 8:26\u201329","journal-title":"Eur J Cancer Care (Engl)"},{"key":"9286_CR75","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugalcdep.2009.07.003","volume":"105","author":"AK Elkader","year":"2009","unstructured":"Elkader AK, Brands B, Callaghan R et al (2009) Exploring the relationship between perceived inter-dose opioid withdrawal and patient characteristics in methadone maintenance treatment. Drug Alcohol Depend 105:209\u2013214","journal-title":"Drug Alcohol Depend"},{"key":"9286_CR76","doi-asserted-by":"publisher","first-page":"e035541","DOI":"10.1136\/bmjopen-2019-035541","volume":"10","author":"K Greenfield","year":"2020","unstructured":"Greenfield K, Holley S, Schoth DE et al (2020) A protocol for a systematic review and meta-analysis to identify measures of breakthrough pain and evaluate their psychometric properties. BMJ Open 10:e035541","journal-title":"BMJ Open"},{"key":"9286_CR77","doi-asserted-by":"crossref","unstructured":"Fallon M, Giusti R, Aielli F et al (2018) Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 29:iv166-iv191","DOI":"10.1093\/annonc\/mdy152"},{"key":"9286_CR78","doi-asserted-by":"publisher","first-page":"e1133","DOI":"10.1634\/theoncologist.2020-0280","volume":"25","author":"DC Currow","year":"2020","unstructured":"Currow DC, Clark K (2020) Opioids for breakthrough cancer pain. Oncologist 25:e1133","journal-title":"Oncologist"},{"key":"9286_CR79","first-page":"302","volume":"208","author":"A Cowan","year":"1974","unstructured":"Cowan A, Ghezzi D, Samanin R (1974) Effect of midbrain raphe lesion and of 6-hydroxydopamine on the antinociceptive action of buprenorphine in rats. Arch Int Pharmacodyn Ther 208:302\u2013305","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"Suppl 1","key":"9286_CR80","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.1191\/0269216306pm1126oa","volume":"20","author":"A Dahan","year":"2006","unstructured":"Dahan A (2006) Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 20(Suppl 1):s3-8","journal-title":"Palliat Med"},{"key":"9286_CR81","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","volume":"96","author":"A Dahan","year":"2006","unstructured":"Dahan A, Yassen A, Romberg R et al (2006) Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96:627\u2013632","journal-title":"Br J Anaesth"},{"key":"9286_CR82","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40265-018-0953-z","volume":"78","author":"MP Davis","year":"2018","unstructured":"Davis MP, Pasternak G, Behm B (2018) Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs 78:1211\u20131228","journal-title":"Drugs"},{"key":"9286_CR83","doi-asserted-by":"publisher","first-page":"e2124152","DOI":"10.1001\/jamanetworkopen.2021.24152","volume":"4","author":"VD Powell","year":"2021","unstructured":"Powell VD, Rosenberg JM, Yaganti A et al (2021) Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review. JAMA Netw Open 4:e2124152","journal-title":"JAMA Netw Open"},{"key":"9286_CR84","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/pme.12520","volume":"15","author":"D Daitch","year":"2014","unstructured":"Daitch D, Daitch J, Novinson D et al (2014) Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med 15:2087\u20132094","journal-title":"Pain Med"},{"key":"9286_CR85","doi-asserted-by":"crossref","unstructured":"Daitch J, Frey ME, Silver D et al (2012) Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician 15:ES59\u201366","DOI":"10.36076\/ppj.2012\/15\/ES59"},{"issue":"10","key":"9286_CR86","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1089\/jpm.2024.0045","volume":"27","author":"MJ Kim","year":"2024","unstructured":"Kim MJ, Walker H, Clark M et al (2024) Inpatient transition from methadone to buprenorphine-naloxone using a microdosing strategy in a postoperative cancer patient: a case report. J Palliat Med 27(10):1421\u20131424","journal-title":"J Palliat Med"},{"key":"9286_CR87","doi-asserted-by":"publisher","first-page":"2310811","DOI":"10.1080\/24740527.2024.2310811","volume":"8","author":"M Rattanavong","year":"2024","unstructured":"Rattanavong M, Kwan D, Jorgenson D et al (2024) Low-dose initiation of buprenorphine\/naloxone for the management of chronic non-cancer pain in patients on long-term opioid therapy: a case series. Can J Pain 8:2310811","journal-title":"Can J Pain"},{"key":"9286_CR88","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/dar.13826","volume":"43","author":"T Naren","year":"2024","unstructured":"Naren T, Cook J, MacCartney P et al (2024) Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine. Drug Alcohol Rev 43:1013\u20131018","journal-title":"Drug Alcohol Rev"},{"key":"9286_CR89","doi-asserted-by":"publisher","first-page":"209261","DOI":"10.1016\/j.josat.2023.209261","volume":"158","author":"BT Hayes","year":"2024","unstructured":"Hayes BT, Li P, Nienaltow T et al (2024) Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: a retrospective cohort study. J Subst Use Addict Treat 158:209261","journal-title":"J Subst Use Addict Treat"},{"key":"9286_CR90","doi-asserted-by":"crossref","unstructured":"Bodnar A, Diffenderffer C, Jablonski LA, Bai E, Stewart RW\u00a0(2024) Use of intravenous buprenorphine microdosing to initiate medication for opioid use disorder in a patient with co-occurring pain: case report. J Addict Dis\u00a042(4):567\u2013571","DOI":"10.1080\/10550887.2023.2285201"},{"key":"9286_CR91","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5055\/jom.0853","volume":"20","author":"MP Davis","year":"2024","unstructured":"Davis MP, McPherson ML, Reddy A et al (2024) Conversion ratios: why is it so challenging to construct opioid conversion tables? J Opioid Manag 20:169\u2013179","journal-title":"J Opioid Manag"},{"key":"9286_CR92","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0304-3959(97)00018-3","volume":"72","author":"P Lawlor","year":"1997","unstructured":"Lawlor P, Turner K, Hanson J et al (1997) Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 72:79\u201385","journal-title":"Pain"},{"key":"9286_CR93","first-page":"1029","volume":"14","author":"I Solassol","year":"2005","unstructured":"Solassol I, Caumette L, Bressolle F et al (2005) Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep 14:1029\u20131036","journal-title":"Oncol Rep"},{"key":"9286_CR94","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/01.ftd.0000160717.50704.42","volume":"27","author":"I Solassol","year":"2005","unstructured":"Solassol I, Bressolle F, Caumette L et al (2005) Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit 27:491\u2013498","journal-title":"Ther Drug Monit"},{"key":"9286_CR95","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00228-012-1266-x","volume":"68","author":"T Naito","year":"2012","unstructured":"Naito T, Tashiro M, Yamamoto K et al (2012) Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol 68:1411\u20131418","journal-title":"Eur J Clin Pharmacol"},{"key":"9286_CR96","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1078155220929415","volume":"27","author":"LD Jackson","year":"2021","unstructured":"Jackson LD, Wortzman R, Chua D et al (2021) Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: a case report and review of the literature. J Oncol Pharm Pract 27:238\u2013243","journal-title":"J Oncol Pharm Pract"},{"key":"9286_CR97","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1248\/bpb.b19-01086","volume":"43","author":"T Chiba","year":"2020","unstructured":"Chiba T, Takahashi H, Tairabune T et al (2020) Cancer cachexia may hinder pain control when using fentanyl patch. Biol Pharm Bull 43:873\u2013878","journal-title":"Biol Pharm Bull"},{"key":"9286_CR98","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pain.2009.04.012","volume":"144","author":"T Heiskanen","year":"2009","unstructured":"Heiskanen T, Matzke S, Haakana S et al (2009) Transdermal fentanyl in cachectic cancer patients. Pain 144:218\u2013222","journal-title":"Pain"},{"issue":"1","key":"9286_CR99","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1016\/j.jpainsymman.2024.03.019","volume":"68","author":"M Davis","year":"2024","unstructured":"Davis M (2024) Fentanyl pharmacokinetic paradoxical in cancer cachexia. J Pain Symptom Manage 68(1):e78","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR100","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/0269216311406577","volume":"25","author":"S Mercadante","year":"2011","unstructured":"Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504\u2013515","journal-title":"Palliat Med"},{"key":"9286_CR101","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4297\/najms.2011.3348","volume":"3","author":"RR Dalacorte","year":"2011","unstructured":"Dalacorte RR, Rigo JC, Dalacorte A (2011) Pain management in the elderly at the end of life. N Am J Med Sci 3:348\u2013354","journal-title":"N Am J Med Sci"},{"key":"9286_CR102","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/10499091221123008","volume":"40","author":"CE Rowe","year":"2023","unstructured":"Rowe CE, Wong AK, Buizen L et al (2023) Do patient demographics and performance status influence opioid dose in cancer pain? Am J Hosp Palliat Care 40:607\u2013612","journal-title":"Am J Hosp Palliat Care"},{"key":"9286_CR103","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"J Pergolizzi","year":"2008","unstructured":"Pergolizzi J, Boger RH, Budd K et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287\u2013313","journal-title":"Pain Pract"},{"key":"9286_CR104","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/apm.2020.03.05","volume":"9","author":"ML McPherson","year":"2020","unstructured":"McPherson ML (2020) Why equianalgesic tables are only part of the answer to equianalgesia. Ann Palliat Med 9:537\u2013541","journal-title":"Ann Palliat Med"},{"key":"9286_CR105","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0022-3565(25)30874-8","volume":"201","author":"G Sacchetti","year":"1977","unstructured":"Sacchetti G, Caputo G, Mandelli V et al (1977) Biliary colic as a model for assessing analgesic activity in man. J Pharmacol Exp Ther 201:444\u2013449","journal-title":"J Pharmacol Exp Ther"},{"key":"9286_CR106","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1749-6632.1948.tb27249.x","volume":"51","author":"LC Miller","year":"1948","unstructured":"Miller LC (1948) A critique of analgesic testing methods. Ann N Y Acad Sci 51:34\u201350","journal-title":"Ann N Y Acad Sci"},{"key":"9286_CR107","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jama.1954.02950030022008","volume":"156","author":"L Lasagna","year":"1954","unstructured":"Lasagna L, Beecher HK (1954) The optimal dose of morphine. J Am Med Assoc 156:230\u2013234","journal-title":"J Am Med Assoc"},{"key":"9286_CR108","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0304-3959(81)90099-3","volume":"10","author":"JD Levine","year":"1981","unstructured":"Levine JD, Gordon NC, Smith R et al (1981) Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain 10:379\u2013389","journal-title":"Pain"},{"key":"9286_CR109","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.jpainsymman.2010.03.005","volume":"40","author":"A Kotlinska-Lemieszek","year":"2010","unstructured":"Kotlinska-Lemieszek A (2010) Rotation, partial rotation (semi-switch), combining opioids, and titration. Does \u201copioid plus opioid\u201d strategy make a step forward on our way to improving the outcome of pain treatment? J Pain Symptom Manage 40:e10-2","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR110","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jpainsymman.2018.12.001","volume":"57","author":"ML McPherson","year":"2019","unstructured":"McPherson ML, Walker KA, Davis MP et al (2019) Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage 57:635-645.e4","journal-title":"J Pain Symptom Manage"},{"key":"9286_CR111","doi-asserted-by":"crossref","unstructured":"Patel MI, Lopez AM, Blackstock W, Reeder-Hayes K, Moushey EA, Phillips J et al (2020) Cancer disparities and health equity: a policy statement from the American Society of Clinical Oncology. J Clin Oncol\u00a038(29):3439\u20133448","DOI":"10.1200\/JCO.20.00642"},{"key":"9286_CR112","volume-title":"Cancer facts & figures for African American\/Black people 2022\u20132024","author":"American Cancer Society","year":"2022","unstructured":"American Cancer Society (2022) Cancer facts & figures for African American\/Black people 2022\u20132024. American Cancer Society, Atlanta"},{"key":"9286_CR113","volume-title":"Cancer facts & figures for Hispanic\/Latino people 2021\u20132023","author":"American Cancer Society","year":"2021","unstructured":"American Cancer Society (2021) Cancer facts & figures for Hispanic\/Latino people 2021\u20132023. American Cancer Society, Atlanta"},{"key":"9286_CR114","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1056\/NEJMsa2034159","volume":"385","author":"NE Morden","year":"2021","unstructured":"Morden NE, Chyn D, Wood A et al (2021) Racial inequality in prescription opioid receipt - role of individual health systems. N Engl J Med 385:342\u2013351","journal-title":"N Engl J Med"},{"key":"9286_CR115","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1200\/OP.20.00773","volume":"17","author":"LK Vitzthum","year":"2021","unstructured":"Vitzthum LK, Nalawade V, Riviere P et al (2021) Racial, ethnic, and socioeconomic discrepancies in opioid prescriptions among older patients with cancer. JCO Oncol Pract 17:e703\u2013e713","journal-title":"JCO Oncol Pract"},{"key":"9286_CR116","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.2011.39.2381","volume":"30","author":"MJ Fisch","year":"2012","unstructured":"Fisch MJ, Lee JW, Weiss M et al (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30:1980\u20131988","journal-title":"J Clin Oncol"},{"key":"9286_CR117","doi-asserted-by":"crossref","unstructured":"Enzinger AC, Ghosh K, Keating NL, Cutler DM, Landrum MB, Wright AA\u00a0(2021) US trends in opioid access among patients with poor prognosis cancer near the end-of-life. J Clin Oncol 39(26):2948\u20132958","DOI":"10.1200\/JCO.21.00476"},{"key":"9286_CR118","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.3390\/curroncol30060437","volume":"30","author":"H Harsanyi","year":"2023","unstructured":"Harsanyi H, Cuthbert C, Schulte F (2023) The stigma surrounding opioid use as a barrier to cancer-pain management: an overview of experiences with fear, shame, and poorly controlled pain in the context of advanced cancer. Curr Oncol 30:5835\u20135848","journal-title":"Curr Oncol"},{"key":"9286_CR119","doi-asserted-by":"publisher","first-page":"10754","DOI":"10.3390\/ijms241310754","volume":"24","author":"L Agullo","year":"2023","unstructured":"Agullo L, Aguado I, Muriel J et al (2023) Pharmacogenetic guided opioid therapy improves chronic pain outcomes and comorbid mental health: a randomized, double-blind, controlled study. Int J Mol Sci 24:10754","journal-title":"Int J Mol Sci"},{"key":"9286_CR120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2133\/dmpk.19.83","volume":"19","author":"S Ozawa","year":"2004","unstructured":"Ozawa S, Soyama A, Saeki M et al (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1. Drug Metab Pharmacokinet 19:83\u201395","journal-title":"Drug Metab Pharmacokinet"},{"key":"9286_CR121","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1185\/030079902125001272","volume":"18","author":"J Menten","year":"2002","unstructured":"Menten J, Desmedt M, Lossignol D et al (2002) Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 18:488\u2013498","journal-title":"Curr Med Res Opin"},{"key":"9286_CR122","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1185\/03007998609110446","volume":"10","author":"MA Nasar","year":"1986","unstructured":"Nasar MA, McLeavy MA, Knox J (1986) An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly. Curr Med Res Opin 10:251\u2013255","journal-title":"Curr Med Res Opin"},{"key":"9286_CR123","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/AJP.0b013e3181673b65","volume":"24","author":"R Likar","year":"2008","unstructured":"Likar R, Vadlau EM, Breschan C et al (2008) Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain 24:536\u2013543","journal-title":"Clin J Pain"},{"key":"9286_CR124","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/pds.3934","volume":"25","author":"NA West","year":"2016","unstructured":"West NA, Dart RC (2016) Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiol Drug Saf 25:539\u2013544","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9286_CR125","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5811\/westjem.2018.5.37853","volume":"19","author":"EM Marra","year":"2018","unstructured":"Marra EM, Mazer-Amirshahi M, Mullins P et al (2018) Opioid administration and prescribing in older adults in U.S. emergency departments (2005\u20132015). West J Emerg Med 19:678\u2013688","journal-title":"West J Emerg Med"},{"key":"9286_CR126","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.amjopharm.2006.12.005","volume":"4","author":"P Sawyer","year":"2006","unstructured":"Sawyer P, Bodner EV, Ritchie CS et al (2006) Pain and pain medication use in community-dwelling older adults. Am J Geriatr Pharmacother 4:316\u2013324","journal-title":"Am J Geriatr Pharmacother"},{"key":"9286_CR127","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1526-4637.2008.00551.x","volume":"10","author":"R Gallagher","year":"2009","unstructured":"Gallagher R (2009) Methadone: an effective, safe drug of first choice for pain management in frail older adults. Pain Med 10:319\u2013326","journal-title":"Pain Med"},{"key":"9286_CR128","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1089\/jpm.2016.0246","volume":"19","author":"T Vu Bach","year":"2016","unstructured":"Vu Bach T, Pan J, Kirstein A et al (2016) Use of methadone as an adjuvant medication to low-dose opioids for neuropathic pain in the frail elderly: a case series. J Palliat Med 19:1351\u20131355","journal-title":"J Palliat Med"},{"key":"9286_CR129","doi-asserted-by":"publisher","first-page":"2310132","DOI":"10.1080\/07853890.2024.2310132","volume":"56","author":"WH Janssens","year":"2024","unstructured":"Janssens WH, Van Den Noortgate NJ, Mouton V et al (2024) Opioids in geriatric units in 14 Belgian hospitals: prevalence, dosage and associated factors. Ann Med 56:2310132","journal-title":"Ann Med"},{"key":"9286_CR130","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","volume":"8","author":"M Niederberger","year":"2020","unstructured":"Niederberger M, Spranger J (2020) Delphi technique in health sciences: a map. Front Public Health 8:457","journal-title":"Front Public Health"},{"key":"9286_CR131","doi-asserted-by":"publisher","first-page":"26291","DOI":"10.3402\/qhw.v10.26291","volume":"10","author":"D Guzys","year":"2015","unstructured":"Guzys D, Dickson-Swift V, Kenny A et al (2015) Gadamerian philosophical hermeneutics as a useful methodological framework for the Delphi technique. Int J Qual Stud Health Well-being 10:26291","journal-title":"Int J Qual Stud Health Well-being"},{"key":"9286_CR132","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.24.00542","volume":"42","author":"JJ Sanders","year":"2024","unstructured":"Sanders JJ, Temin S, Ghoshal A et al (2024) Palliative care for patients with cancer: ASCO guideline update. J Clin Oncol 42:2336\u20132357","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09286-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:27:27Z","timestamp":1747722447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09286-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9286"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09286-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"RA, SM, AK, ED, MPD are on the editorial board of the JSCC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}